Enhance the standard of care for sepsis —
by detecting bloodstream infections sooner
The T2Bacteria® Panel is the first and only FDA-cleared and CE-marked panel to detect five clinically relevant bacterial pathogens in 3 to 5 hours, directly from a whole blood sample. E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, and E. coli represent the majority of bacteremia seen in the emergency department1 and those causing hospital-acquired infections2. In addition, several of these species are known as ESKAPE pathogens3, characterized as virulent and difficult to treat with empiric antimicrobial therapy, making faster species identification and targeted treatment critical to improving patient outcomes2.
ESKAPE pathogens represent the majority of bloodstream infections and lead to negative clinical and economic outcomes
Bacterial bloodstream infections may lead to sepsis. In the absence of species-specific diagnostic information, clinical treatment of sepsis begins with the initiation of empiric therapy. Despite the broad coverage of empiric therapy, it may not adequately address all pathogens, with studies demonstrating that 1 in 5 patients with bloodstream infections receive discordant treatment, which is associated with increased odds of mortality.5 Fast, targeted antimicrobial therapy is especially important for patients in septic shock, whose mortality risk increases by 8% for every hour of delayed appropriate treatment.6
The positive clinical impact of T2Bacteria
Target therapy sooner by reducing the time to species ID7
T2Bacteria was shown to identify targeted species of bacteria ~66 hours faster than blood culture
40% of subjects in the clinical trial may have benefited from the initiation of or a change in therapy 2-days faster with a T2Bacteria result as compared to blood culture alone
Increase clinician confidence in treatment with accurate and reliable results6
Limit of detection (LoD) 2-11 CFU/mL
Unlike blood culture, T2MR Technology is not susceptible to interference from common antimicrobials
Impact patient outcomes and reduce length of stay for patients with bloodstream infections8
T2MR has demonstrated a 5-day reduction intensive care unit (ICU) stay
T2MR has demonstrated a 4.8-day reduction in hospital length of stay
Improve antimicrobial stewardship
Opportunity to escalate or de-escalate therapy sooner7
Potential to reduce the overuse of antimicrobials and limit side-effects
Real-World Case Studies
Real-world clinical case studies have proven the clinical utility of both positive and negative results using the T2Bacteria Panel. Read our case studies to learn more.
Voigt, Christopher, et al. “The T2Bacteria assay Is a sensitive and rapid detector of bacteremia that can be initiated in the emergency department and has potential to favorably influence subsequent therapy.” The Journal of Emergency Medicine. 2020.
Timsit, JF, et al. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020
Marturano JE, Lowery TJ. ESKAPE Pathogens in Bloodstream Infections Are Associated With Higher Cost and Mortality but Can Be Predicted Using Diagnoses Upon Admission. Open Forum Infect Dis. 2019
Diekema, Daniel J., et al. “The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program.” Antimicrobial Agents and Chemotherapy. 2019.
Kadri SS, Lai YL, Warner S, et al, Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021
Kumar, A., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine. 2006.
Nguyen H, et al. Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections: A Diagnostic Accuracy Study. Ann Intern Med. 2019.
Giannella, Maddalena, et al. Expert Review of Medical Devices. 2021.
Sensitivity: 90%7 Specificity: 98%7
E. faecium S. aureus K. pneumoniae P. aeruginosa E. coli
T2 BIOSYSTEMS OVERVIEW
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.